Die Studie

Clinical trial of a new compound that is being developed for cardiovascular diseases.

In this study, the safety and tolerability of the study compound is investigated when administered to healthy participants. The study compound will be tested at various dose levels.

  • You are a healthy male or female between 21 and 60 years old.
  • Your Body Mass Index (BMI) is between 18.0 and 30.0 kg/m2.
  • You do not smoke or use nicotine containing products.


  • You cannot participate in the trial if you have participated in another clinical trial in the 3 months prior to the screening of this clinical trial (counting from the follow-up visit).
  • To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.

As a female you can only participate if you are not pregnant and not breast feeding and meet one of the following conditions:

  • You have passed the menopause (no menstrual cycle for at least 12 months);
  • You have been sterilized;

As a male you can only participate if you meet one of the following conditions:

  • You are using a condom in combination with a contraception method used by your female partner;
  • You have been sterilized or your female partner is sterilized or postmenopausal;
  • You abstain from heterosexual intercourse (you are not sexually active) according to your lifestyle.


Group 4b  
  • 31 Jan 2022 up to and including 3 Feb 2022
follow-up by appointment between 17 and 24 Feb 2022.


You will receive a gross compensation of € 1112 for participation in one of the groups.

Travel expenses will be reimbursed based on the distance traveled (€ 0.19 net per kilometer) with a minimum of € 12 and a maximum of € 160 (840 kilometers) per round trip, regardless of the mode of transportation.